Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 1-Year Results from PRECiSE 4

被引：0
|
作者：
Sandborn, William [1 ]
Rubin, David [2 ]
Sen, David [3 ]
Feagan, Brian [4 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA 92093 USA
[2] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[3] UCB Inc, Raleigh, NC USA
[4] Univ Western Ontario, Robarts Res Inst, London, ON, Canada
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2011年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1171
引用
收藏
页码：S439 / S439
页数：1
相关论文
共 50 条
  • [41] Long-Term Remission With Certolizumab Pegol in Crohn's Disease: Efficacy Over 4 Years in Patients With NO Prior TNF-α Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole O.
    Schreiber, Stefan
    Lawrance, Ian C.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [42] Improved health-related quality of life after certolizumab pegol 400 mg every 4 weeks in patients with Crohn's disease: Data from PRECiSE 2
    Feagan, Brian G.
    Keininger, Dorothy L.
    Coteur, Geoffroy
    Schreiber, Stefan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S404 - S405
  • [43] Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results
    Schreiber, Stefan
    Hanauer, Stephen B.
    Feagan, Brian G.
    Bloomfield, Ralph
    Rutgeerts, Paul
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A504 - A504
  • [44] Certolizumab Pegol Demonstrates Efficacy in Maintaining Response and Remission in Patients With Active Crohn's Disease Regardless of Their Immunosuppressant Treatment Status at Entry to the PRECiSE 2 Study
    Schreiber, Stefan
    Khaliq-Kareemi, Munaa
    Lawrance, Ian C.
    Thomsen, Ole O.
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S165 - S165
  • [45] Rapid onset of response and remission to subcutaneous certolizumab pegol and lack of influence of concomitant baseline medications in active Crohn disease: Results from the open-label induction phase of the precise 2 study
    Thomsen, Ole O.
    Screiber, Stefan
    Khaliq-Kareemi, Munaa
    Hanauer, Stephen B.
    Bloomfield, Ralph
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A505 - A505
  • [46] Long-term remission with certolizumab pegol in Crohn's disease: Efficacy over 4.5 years in patients with no prior TNF inhibitor exposure (PRECiSE 3 study).
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S51 - S52
  • [47] Long-term Remission with Certolizumab Pegol in Crohn's Disease: Efficacy Over 4.5 Years in Patients with No Prior TNF Inhibitor Exposure (PRECiSE 3 Study)
    Lichtenstein, Gary
    Thomsen, Ole
    Schreiber, Stefan
    Lawrance, Ian
    Hanauer, Stephen
    Bloomfield, Ralph
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S417 - S418
  • [48] Safety and tolerability of subcutaneous (SC) certolizumab pegol in active Crohn's disease (CD): Results from two phase III studies (PRECISE program)
    Schreiber, Stefan
    Feagan, Brian
    Hanauer, Stephen B.
    Rutgeerts, Paul
    McColm, Joliet A.
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A479 - A479
  • [49] Long-Term Safety and Efficacy of Certolizumab Pegol Therapy in Patients With Moderate to Severe Crohn's Disease: 5-Year Results
    Ptak, Theadore
    Younes, Ziad
    Shafran, Ira
    Lee, Scott
    Miner, Philip B.
    Kayhan, Cem
    Kosutic, Gordana
    Coarse, Jason
    Hasan, Iram
    Spearman, Marshall
    Sandborn, William J.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 : S774 - S775
  • [50] Can We Use Objective Markers to Predict Which Crohn's Disease Patients Will Achieve Remission With Certolizumab Pegol? Testing the PRECiSE 3 Identified Predictors of Remission in a Real World Population
    Udawatta, Viyan
    Rivers, Claudia Ramos
    Click, Benjamin H.
    Hasan, Iram
    Spearman, Marshall
    Kosutic, Gordana
    Coarse, Jason
    Dunn, Michael A.
    Regueiro, Miguel
    Binion, David G.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S802 - S803
12345